190 365

Cited 0 times in

Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry

DC Field Value Language
dc.contributor.authorYi, HG-
dc.contributor.authorKim, JS-
dc.contributor.authorSuh, C-
dc.contributor.authorKim, WS-
dc.contributor.authorKwak, JY-
dc.contributor.authorLee, JS-
dc.contributor.authorKim, YS-
dc.contributor.authorJoo, YD-
dc.contributor.authorMin, YH-
dc.contributor.authorLee, HG-
dc.contributor.authorYoon, SS-
dc.contributor.authorWon, JH-
dc.contributor.authorPark, S-
dc.contributor.authorKim, HC-
dc.contributor.authorKim, CS-
dc.date.accessioned2014-07-10T04:32:54Z-
dc.date.available2014-07-10T04:32:54Z-
dc.date.issued2013-
dc.identifier.issn2287-979X-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/10533-
dc.description.abstractBackground: This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes.



Methods: In 2007‒2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at www.lymphoma.or.kr and filed a total of 1,665 cases of DLBCL recorded since 1990.



Results: Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53% vs. 47%). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low- and low-intermediate-risk groups according to IPI scores significantly increased survival duration.



Conclusion: The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.
-
dc.language.isoen-
dc.titleClinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry-
dc.typeArticle-
dc.identifier.urlhttp://www.bloodresearch.or.kr/journal/view.html?uid=2051-
dc.subject.keywordDiffuse large B-cell lymphoma-
dc.subject.keywordEpidemiology-
dc.subject.keywordSurvival-
dc.subject.keywordRituximab-
dc.subject.keywordCHOP regimen-
dc.contributor.affiliatedAuthor김, 효철-
dc.type.localJournal Papers-
dc.citation.titleBlood research-
dc.citation.volume48-
dc.citation.number2-
dc.citation.date2013-
dc.citation.startPage115-
dc.citation.endPage120-
dc.identifier.bibliographicCitationBlood research, 48(2):115-120, 2013-
dc.identifier.eissn2288-0011-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Files in This Item:
Blood research_48(2)_115-120.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse